Conceived and designed the experiments: JS YW JK EH JU. Performed the experiments: JS JL JK JU. Analyzed the data: JS JL YW JK JB EH JU. Wrote the paper: JS JL YW JK EH JU.
Metabolic profiling holds promise with regard to deepening our understanding of infection biology and disease states. The objectives of our study were to assess the global metabolic responses to an
Twelve female NMRI mice were infected with 30
The current investigation is part of a broader NMR-based metabonomics profiling strategy and confirms the utility of this approach for biomarker discovery. In the case of
Consumption of raw fish and other freshwater products can lead to unpleasant worm infections. Indeed, such worm infections are of growing public health and veterinary concern, but they are often neglected, partially explained by the difficulty of accurate diagnosis. In the present study we infected 12 mice with an intestinal worm (i.e.,
An estimated 40 million individuals are infected with food-borne trematodes and, in many parts of the world, the diseases caused by these infections are emerging
A light infection with the intestinal fluke
At present, the most widely used diagnosis for infections with
In the current study we applied a combination of 1H nuclear magnetic resonance (NMR) spectroscopy and multivariate statistical analysis to identify candidate biomarkers of an
Our experiments were carried out in accordance with Swiss cantonal and national regulations on animal welfare (permission no. 2081). Female NMRI mice (n = 24) were purchased from RCC (Itingen, Switzerland), and housed in groups of 4 in macrolon cages under environmentally-controlled conditions (temperature: ∼25°C; humidity: ∼70%; light-dark cycle: 12–12 h). Mice had free access to commercially available rodent food from Nafag (Gossau, Switzerland) and community tap water supply.
Mice were 5 to 6-week-old at the onset of the experiments and had an average weight of 25.5 g (standard deviation (SD) = 0.9 g). Half of the mice remained uninfected throughout the study and served as controls. The other 12 mice were orally infected with 30
Blood plasma, stool and urine samples were collected over a 33-day time course at 7 distinct sampling points (days 1, 5, 8, 12, 19, 26, and 33 post-infection), representative of different stages in the life of the
Mice were killed 36 days post-infection, using CO2. The small intestine was removed, and adult worms recovered from the ileum and jejunum and counted. Biological samples and an
Urine samples were prepared with a phosphate buffer (pH 7.4) containing 50% D2O (Goss Scientific Instruments; Chelmsford, United Kingdom) as a field frequency lock and 0.01% sodium 3-(trimethylsilyl) [2,2,3,3-2H4] propionate (TSP) (Cambridge Isotope Laboratories Inc.; Andover, MA, United States of America), as a chemical shift reference (δ 0.0). An aliquot of 25 μl of urine was added to 25 μl phosphate buffer. Plasma samples were prepared by adding 30 μl of 0.9% saline made up in 50% D2O into the Eppendorf tubes containing ∼20 μl of plasma. Because of the limited volumes of urine and plasma, samples were transferred into 1.7 mm diameter micro NMR-tubes (CortecNet; Paris, France) using a micro-syringe.
Stool samples were prepared with the same buffer as for urine but using 90% D2O to reduce the water content. Two pellets of stool were mashed with 700 μl buffer and sonicated for 30 min to inactivate gut bacteria and achieve biochemical stability in the sample. The samples were then centrifuged at 10,000 g for 2 min, and 550–600 μl of the supernatant was transferred into a new Eppendorf tube and stored at −40°C. Shortly before data acquisition, the stool supernatant was defrosted, centrifuged and transferred into NMR tubes of 5 mm outer diameter.
A tissue extraction was performed on the
1H NMR spectra from plasma, stool, and urine samples, and the
Assignments of the spectral peaks were made from literature values
Data processing was as follows. First, spectra were corrected for phase and baseline distortions with an in-house developed MATLAB script. Second, the region containing the water/urea resonances (i.e., δ 4.2–6.3 in urine, δ 4.4–5.2 in plasma, and δ 4.7–5.5 in stool extracts) was excluded. Third, the spectra were normalized over the total sum of the remaining spectral area. Analysis of the spectral data was performed with principal component analysis (PCA)
The NMR spectral data were used as the
Finally, in order to more accurately profile the temporal behavior of the discriminatory metabolites characterizing an
Prior to assessing the metabolic effects of an
Spectra of urine (
Spectra of urine (
| Metabolite | Maximal time of metabolic change | Chemical moiety | Chemical shift in ppm and multiplicity |
| 2-hydroxyisobutyrate | 2×CH3 | 1.36(s) | |
| 2-ketoisocaproate | ↓ (d12) | CH2, CH, 2×CH3 | 2.61(d), 2.10(m), 0.94(d) |
| 2-oxoglutarate | β-CH2, γ-CH2 | 3.02(t), 2.50(t) | |
| acetate | ↓ (d8) | CH3 | 1.91(s) |
| alanine | α-CH, β-CH3 | 3.81(q), 1.48(d) | |
| allantoin | CH | 5.40(s) | |
| citrate | 1-CH2, 3-CH2 | 2.69(d), 2.54(d) | |
| creatine | ↓ (d8) | CH3, CH2 | 3.04(s), 3.93(s) |
| creatinine | CH3, CH2 | 3.05(s), 4.06(s) | |
| dimethylamine | 2×CH3 | 2.71(s) | |
| dimethylglycine | 2×CH3, CH2 | 2.89(s), 3.71(s) | |
| formate | CH | 8.45(s) | |
| fumarate | CH | 6.53(s) | |
| α-glucose | ↑ (d1); ↓ (d12)* | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd), 3.85(m) |
| β-glucose | ↑ (d1); ↓ (d12)* | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 4.65(d), 3.25(dd), 3.47(t), 3.40(t), 3.47(ddd), 3.78(dd), 3.90(dd) |
| glycolate | CH2 | 3.94(s) | |
| guanidinoacetate | CH2 | 3.80(s) | |
| hippurate | ↓ (d33) | CH2, 2,6-CH, 3,5-CH, 4-CH | 3.97(d), 7.84(d), 7.55(t), 7.64(t) |
| indoxylsulfate | 5-CH, 6-CH, 4-CH, 7-CH | 7.20(t), 7.27(t), 7.51(d), 7.70(d) | |
| lactate | CH, CH3 | 4.12(q), 1.33(d) | |
| mannitol | ↑ (d12) | 2×α-CH2, 2×β-CH, 2×γ-CH | 3.78(m), 3.88(dd), 3.68(dd) |
| methylcrotonate | β-CH, γ-CH3, γ′-CH3 | 1.66(s), 1.70(s), 1.71(s) | |
| methylamine | CH3 | 2.61(s) | |
| methylguanidine | CH3 | 2.83(s) | |
|
|
CH3, 6-CH, 2-CH, 5-CH, 4-CH | 4.48(s), 8.97(d), 9.28(s), 8.19(t), 8.90(d) | |
|
|
↑ (d12) | 2,6-CH, 3,5-CH, CH3 | 7.06(d), 7.23(d), 2.30(s) |
| phenylacetylglycine | ↑ (d26) | 2,6-CH, 3,5-CH, Ph-CH2, |
7.43(m), 7.37(m), 3.75(d), 3.68(s) |
| pyridoxamine-5-phosphate | OCH2, CH2N, CH3 | 7.67(s), 4.34(s), 2.48(s) | |
| succinate | ↑ (d33) | 2×CH2 | 2.41(s) |
| taurine | ↓ (d19) | CH2N, CH2S | 3.27(t), 3.43(t) |
| trimethylamine | ↑ (d12) | 3×CH3 | 2.88(s) |
| trimethylamine- |
↑ (d12) | 3×CH3 | 3.27(s) |
| ureidopropanoate | α-CH2, β-CH2 | 2.38(t), 3.3(t) | |
| urocanate | α-CH, β-CH, 5-CH, 2-CH | 6.40(d), 7.13(d), 7.41(s), 7.89(s) |
The arrows show whether the metabolic change, associated with an
| Metabolite | Maximal time of metabolic change | Chemical moiety | Chemical shift in ppm and multiplicity |
| 2-ketoisovalerate | CH, 2×CH3 | 3.02(m), 1.13(d) | |
| 3-hydroxybutyrate | half α-CH2, half α-CH2, β-CH, γ-CH3 | 2.32(m), 2.42(m), 4.16(m), 1.21(d) | |
| acetate | ↑ (d12) | CH3 | 1.91(s) |
| acetoacetate | α-CH2, γ-CH3 | 2.29(s), 3.45(s) | |
| alanine | α-CH, β-CH3 | 3.81(q), 1.48(d) | |
| allantoin | CH | 5.40(s) | |
| choline | ↓ (d33) | 3×CH3, α-CH2, β-CH2 | 3.21(s), 4.07(m), 3.52(m) |
| citrate | 1-CH2, 3-CH2 | 2.69(d), 2.54(d) | |
| creatine | ↓ (d12) | CH3, CH2 | 3.04(s), 3.93(s) |
| dihydroxythymine | CH2, CH, CH3 | 3.17(m), 2.47(m), 1.07(d) | |
| formate | ↑ (d12) | CH | 8.45(s) |
| α-glucose | ↑ (d1); ↓ (d12)* | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd), 3.85(m) |
| β-glucose | ↑ (d1); ↓ (d12)* | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 4.65(d), 3.25(dd), 3.47(t), 3.40(t), 3.47(ddd), 3.78(dd), 3.90(dd) |
| glycerophosphocholine | ↓ (d12) | 3×CH3, half α-CH2, half α-CH2, half β-CH2, half β-CH2, γ-CH2 | 3.23(s), 4.32(t), 3.60(dd), 3.68(t), 3.89(m), 3.72(dd) |
| isoleucine | ↓ (d33) | α-CH, β-CH, half γ-CH2, half γ-CH2, δ-CH3, β-CH3 | 3.68(d), 1.93(m), 1.25(m), 1.47(m), 0.99(d), 1.02(d) |
| lactate | CH, CH3 | 4.12(q), 1.33(d) | |
| leucine | ↓ (d33) | α-CH, β-CH2, γ-CH, δ-CH3, δ-CH3 | 3.72(t), 1.63(m), 1.69(m), 0.91(d), 0.94(d) |
| methionine | α-CH, β-CH2, γ-CH2, CH3 | 3.87(m), 2.10(m), 2.65(dd), 2.15(s) | |
|
|
6×CH | 3.35(s) | |
| valine | ↓ (d33) | α-CH, β-CH, γ-CH3, γ′-CH3 | 3.62(d), 2.28(m), 0.98(d), 1.03(d) |
| lipid fraction | ↑ | CH3 | 0.84(t) |
| lipid fraction | ↑ | (CH2)n | 1.25(m) |
| lipid fraction | ↑ | β-CH2CH2CO | 1.57(m) |
| lipid fraction | ↑ | CH2C = C | 1.97(m), 2.00(m) |
| lipid fraction | ↑ | CH2CO | 2.23(m) |
| lipid fraction | ↑ | C = CCH2C = C | 2.69(m), 2.71(m), 2.72(m) |
| lipid fraction | ↑ | CH = CH | 5.23(m), 5.26(m), 5.29(m) |
Arrows indicate significantly changing substances comparing plasma of
| Metabolite | Maximal time of metabolic change | Chemical moiety | Chemical shift in ppm and multiplicity |
| 2-hydroxyisovalerate | α-CH, β-CH, γ-CH3, γ′-CH3 | 3.85(d), 2.02(m), 0.79(d), 0.84(d) | |
| 2-ketoisocaproate | CH2, CH, 2×CH3 | 2.61(d), 2.10(m), 0.94(d) | |
| 2-ketoisovalerate | CH, 2×CH3 | 3.02(m), 1.13(d) | |
| 3-aminopropionic acid | α-CH2, β-CH2 | 2.56(t), 3.19(t) | |
| 3-hydroxyphenylpropionate | α-CH2, β-CH2, 2-CH | 2.85(t), 2.47(m), 6.80(m) | |
| 2-oxoisoleucine | CH, half γ-CH2, half γ-CH2, δ-CH3, β-CH-CH3 | 2.93(m), 1.70(m), 1.46(m), 0.90(t), 1.10(d) | |
| 5-aminovalerate | ↑ (d26) | 5-CH2, 2-CH2, 3,4-CH2 | 3.02(t), 2.24(t), 1.65(m) |
| acetate | ↓ (d12) | CH3 | 1.91(s) |
| alanine | ↓ (d12) | α-CH, β-CH3 | 3.81(q), 1.48(d) |
| arginine | α-CH, β-CH2, γ-CH2, δ-CH2 | 3.76(t), 1.89(m), 1.59(m), 3.17(t) | |
| asparagine | α-CH, half β-CH2, half β-CH2 | 4.01(m), 2.87(dd), 2.96(dd) | |
| aspartate | α-CH, half β-CH2, half β-CH2 | 3.92(m), 2.70(m), 2.81(m) | |
| bile acids | CH3 | 0.70(m) | |
| butyrate | ↓ (d26) | α-CH2, β-CH2, γ-CH3 | 2.16(t), 1.56(m), 0.90(t) |
| ethanolamine | NH-CH2, HO-CH2 | 3.15(t), 3.78(t) | |
| formate | CH | 8.45(s) | |
| fumarate | CH | 6.53(s) | |
| α-glucose | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd), 3.85(m) | |
| β-glucose | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 4.65(d), 3.25 (dd), 3.47(t), 3.40(t), 3.47(ddd), 3.78(dd), 3.90(dd) | |
| glutamate | α-CH, β-CH2, γ-CH2 | 3.78(m), 2.06(m), 2.36(m) | |
| glutamine | α-CH, β-CH2, γ-CH2 | 3.78(m), 2.15(m), 2.46(m) | |
| glycerol | half α-CH2, half α-CH2, β-CH | 3.56(dd), 3.64(dd), 3.87(m) | |
| glycine | ↓ (d12) | CH2 | 3.55(s) |
| hypoxanthine | 3-CH, 7-CH | 8.10(s), 8.11(s) | |
| isoleucine | ↑ (d26) | α-CH, β-CH, half γ-CH2, half γ-CH2, δ-CH3, β-CH3 | 3.68(d), 1.93(m), 1.25(m), 1.47(m), 0.99(d), 1.02(d) |
| lactate | CH, CH3 | 4.12(q), 1.33(d) | |
| leucine | ↑ (d8) | α-CH, β-CH2, γ-CH, δ-CH3, δ-CH3 | 3.72(t), 1.63(m), 1.69(m), 0.91(d), 0.94(d) |
| lysine | α-CH, β-CH2, γ-CH2, δ-CH2, ε-CH2 | 3.77(t), 1.92(m), 1.73(m), 1.47(m), 3.05(t) | |
| methionine | α-CH, β-CH2, γ-CH2, CH3 | 3.87(m), 2.10(m), 2.65(dd), 2.15(s) | |
|
|
1,3-CH, 2-CH, 5-CH, 4,6-CH | 3.53(dd), 4.06(t), 3.28(t), 3.63(t) | |
| phenylacetic acid | CH2, 2,4,6-CH, 3,5-CH | 3.52(s), 7.29(t), 7.36(t) | |
| phenylalanine | 2,6-CH, 3,5-CH, 4-CH, half β-CH2, half β-CH2, α-CH | 7.44(m), 7.39(m), 7.33(m), 3.17(dd), 3.30(dd), 3.99(dd) | |
| proline | α-CH, half β-CH2, half β-CH2, γ-CH2, δ-CH2 | 4.15(dd), 2.05(m), 2.38(m), 2.00(m), 3.39(m) | |
| propionate | ↓ (d26) | CH2, CH3 | 2.19(q), 1.06(t) |
| succinate | 2× CH2 | 2.41(s) | |
| threonine | α-CH, β-CH, γ-CH3 | 3.60(d), 4.26(m), 1.33(d) | |
| tryptophan | 4-CH, 7-CH, 2-CH, 5-CH, 6-CH, α-CH, half β-CH2, half β-CH2 | 7.79(d), 7.56(d), 7.34(s), 7.29(t), 7.21(t), 4.06(dd), 3.49(dd), 3.31(dd) | |
| tyrosine | 2,6-CH, 3,5-CH, CH2, α-CH | 7.23(d), 6.91(d), 2.93(t), 3.25(t) | |
| uracil | ↑ (d8) | 5-CH, 6-CH | 5.81(d), 7.59(d) |
| urocanate | α-CH, β-CH, 5-CH, 2-CH | 6.40(d), 7.13(d), 7.41(s), 7.89(s) | |
| valine | ↑ (d26) | α-CH, β-CH, γ-CH3, γ′-CH3 | 3.62(d), 2.28(m), 0.98(d), 1.03(d) |
Arrows indicate differences in the spectral profiles between
In order to establish whether excretory products of the parasite itself were likely to contribute to any of the biofluids analyzed, a standard 1D spectrum of an adult
| Metabolite | Chemical moiety | Chemical shift in ppm and multiplicity |
| 3-hydroxybutyrate | half α-CH2, half α-CH2, β-CH, γ-CH3 | 2.32(m), 2.42(m), 4.16(m), 1.21(d) |
| acetate | CH3 | 1.91(s) |
| alanine | α-CH, β-CH3 | 3.81(q), 1.48(d) |
| betaine | CH2, CH3 | 3.90(s), 3.27(s) |
| choline | 3×CH3, α-CH2, β-CH2 | 3.21(s), 4.07(m), 3.52(m) |
| formate | CH | 8.45(s) |
| α-glucose | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd), 3.85(m) |
| β-glucose | 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 | 4.65(d), 3.25(dd), 3.47(t), 3.40(t), 3.47(ddd), 3.78(dd), 3.90(dd) |
| glutamine | α-CH, β-CH2, γ-CH2 | 3.78(m), 2.15(m), 2.46(m) |
| glycerophosphocholine | 3×CH3, half α-CH2, half α-CH2, half β-CH2, half β-CH2, γ-CH2 | 3.23(s), 4.32(t), 3.60(dd), 3.68(t), 3.89(m), 3.72(dd) |
| glycine | CH2 | 3.55(s) |
| histidinol | 5-CH, 3-CH, γ-CH2, β-CH, α-CH | 7.89(s), 7.12(s), 3.85(dd), 3.67(m), 3.62(m) |
| homocarnosine | 5-CH, 3-CH, half ring-CH2, half ring-CH2, N-CH, N-CH2, CO-CH2, CH2 | 7.90(s), 7.01(s), 3.17(dd), 2.96(dd), 4.48(m), 2.92(m), 2.36(m), 1.89(m) |
| isoleucine | α-CH, β-CH, half γ-CH2, half γ-CH2, δ-CH3, β-CH3 | 3.68(d), 1.93(m), 1.25(m),1.47(m), 0.99(d), 1.02(d) |
| lactate | CH, CH3 | 4.12(q), 1.33(d) |
| leucine | α-CH, β-CH2, γ-CH, δ-CH3, δ-CH3 | 3.72(t), 1.63(m), 1.69(m), 0.91(d), 0.94(d) |
| lysine | α-CH, β-CH2, γ-CH2, δ-CH2, ε-CH2 | 3.77(t), 1.92(m), 1.73(m), 1.47(m), 3.05(t) |
| methionine | α-CH, β-CH2, γ-CH2, CH3 | 3.87(m), 2.10(m), 2.65(dd), 2.15(s) |
| phenylalanine | 2,6-CH, 3,5-CH, 4-CH, half β-CH2, half β-CH2, α-CH | 7.44(m), 7.39(m), 7.33(m), 3.17(dd), 3.30(dd), 3.99(dd) |
| pipecolate | half 3,4,5-CH2, half 4,5-CH2, half 3-CH2, half 6-CH2, half 6-CH2, 2-CH | 1.60–1.66(m), 1.86(m), 2.22(m), 3.02(m), 3.43(m), 3.60(m) |
| proline | α-CH, half β-CH2, half β-CH2, γ-CH2, δ-CH2 | 4.15(dd), 2.05(m), 2.38(m), 2.00(m), 3.39(m) |
| propionate | CH2, CH3 | 2.19(q), 1.06(t) |
|
|
6×CH | 3.35(s) |
| succinate | 2×CH2 | 2.41(s) |
| threonine | α-CH, β-CH, γ-CH3 | 3.60(d), 4.26(m), 1.33(d) |
| tryptophan | 4-CH, 7-CH, 2-CH, 5-CH, 6-CH, α-CH, half β-CH2, half β-CH2 | 7.79(d), 7.56(d), 7.34(s), 7.29(t), 7.21(t), 4.06(dd), 3.49(dd), 3.31(dd) |
| tyrosine | 2,6-CH, 3,5-CH, CH2, α-CH | 7.23(d), 6.91(d), 2.93(t), 3.25(t) |
| uridine | 6-CH, 5-CH, 2′-CH, 3′-CH, 4′-CH, 5′-CH(d), half CH2OH, half CH2OH | 7.87(d), 5.90(s), 5.92(d), 4.36(t), 4.24(t), 4.14(q), 3.92(dd), 3.81(dd) |
| valine | α-CH, β-CH, γ-CH3, γ′-CH3 | 3.62(d), 2.28(m), 0.98(d), 1.03(d) |
In both PCA and PLS-DA scores plots of the urinary metabolite profiles, a clear separation of
The collection of the biofluids was performed at days 1, 5, 8, 12, 19, 26, and 33 post-infection. The ellipses in the 3D plots (
The plasma spectra of
With regard to the 1H NMR spectra obtained from stool samples, a clear separation was found at day 5 post-infection in both the PCA and PLS-DA scores plot between
O-PLS-DA was used to extract information on specific metabolic changes induced by an
The color scale indicates the relative contribution of the peak/region to the strength of the differentiation model and the peak intensity is measured relative to the whole peak contribution in arbitrary units (a.u.). Note that the aromatic region (left part) is magnified by a factor 5.
The color scale indicates the relative contribution of the peak/region to the strength of the differentiation model and the peak intensity is measured relative to the whole peak contribution in arbitrary units (a.u.). The CPMG spectrum represents small molecular weight components.
The color scale indicates the relative contribution of the peak/region to the strength of the differentiation model and the peak intensity is measured relative to the whole peak contribution in arbitrary units (a.u.). Note that the aromatic region (left part) is magnified by a factor 5.
Plasma from infected mice showed changes in the relative concentration of acetate (increased at all time points except day 5), creatine (decreased from day 8 onwards), lipids (increased from day 8 onwards), formate (decreased at days 1, 8, 12, and 19, but increased at day 33), lactate (decreased at days 1, 8, 12, 19, and 26), glucose (increased at days 1, and 33, but decreased at days 12, 19, and 26), glycerophosphorylcholine (GPC; decreased at days 12, 26, and 33), choline (decreased at days 1, 12, 26, and 33) and branched chain amino acids (BCAAs; decreased at days 12, 26, and 33).
The changes in stool samples from infected animals included the BCAAs (increased at days 8, and 26), uracil (increased at day 8), butyrate (decreased at days 12, 19, and 26), propionate (decreased at days 12, 19, and 26) and 5-aminovalerate (increased from day 5 onwards).
1H NMR-based metabolic profiling of biofluids is an established method for deepening our understanding of host-parasite interactions and for investigating disease states in clinical studies
A number of potential biomarkers for diagnosis of an
The colored regions show the differences between
The relative concentration with respect to the total spectral area of each of these metabolites is shown for non-infected control mice (blue), and
The time trajectories allow the influence of growth and maturation of either host or parasite to be considered. Since very few of the metabolites observed in the
In stool and plasma, the time trajectories of the infected animals demonstrated a markedly greater magnitude from the baseline position than the non-infected animals. The greatest differentiation between
The considerable increase in concentration of lipids in the plasma, e.g., fatty acids, triaglycerols, and lipoproteins, reflects the action of the parasite in the hosts gut. In mice harboring a 2-week-old
Whilst the simple diffusion of lipid micelles into mucosal cells seems unaffected by the parasite, the Na+-dependent active transport of amino acids could be impaired as the increase of the BCAAs in stool as the subsequent decrease in plasma supports. Depletion of the carrier molecules at the brush border of the mucosal cells, or a change of the electrochemical gradient for Na+ might explain the selective impact on trans-luminal gut transport
The observed decrease of leucine in plasma, in turn, might induce the significant reduction in levels of 2-ketoisocaproate in urine, which is a transamination product of the former
The changes in hippurate, phenylacetylglycine,
The decrease of the SCFAs in stool may also be indicative of an unbalanced microbiota, as dietary carbohydrates (e.g., starches and fibres) are fermented by colonic bacteria to mainly acetate, propionate, and butyrate. Whilst butyrate serves as main energy source for colonocytes, acetate and propionate pass through the intestinal wall and move
The increased concentration of TMA and phenylacetylglycine, and the decrease of hippurate in urine, observed at the later time points of our experiment, are concomitant phenomena of the changed gut microbiota
An infection with
To assess the specificity of the biomarkers identified for potential diagnosis of infection, the obtained
Future studies evaluating additional laboratory host-parasite models, and applying complementary metabolic profiling methods, such as ultra performance liquid chromatography (UPLC), in combination with mass spectrometry (MS), will help to confirm the specificity of the metabolic perturbations associated with an
(0.02 MB DOC)
Click here for additional data file.
(0.16 MB PDF)
Click here for additional data file.
The authors thank Dr. Olivier Cloarec for providing the MATLAB script for O-PLS-DA and STOCSY analysis and Mr. Kirill Veselkov for giving access to his peak alignment and normalization script in MATLAB.
The authors have declared that no competing interests exist.
This investigation received financial support from the Swiss National Science Foundation (project no. PPOOB-102883, PPOOB-119129, and PPOOA-114941) and Imperial College London. The authors also acknowledge Nestlé for provision of funds for Y. Wang.